One fiction is that the validity of REVO patents has been confirmed.
REVO's patents legitimacy were undergirded by the patent office when it rejected AF's attempt to file something similar.
No it wasn't. That myth was created by a PR from REVO stating that their patents had been 'upheld'. The USPTO cannot 'uphold' a patent. The USPTO issues patents or rejects patent applications. It issued a patent to Ron Carter, and rejected a similar application by Alarmforce.
Another myth is that the REVO patents have been validated judicially.
REVO has a court case win under their belt
No it doesn't. Two cases, one against Protect America and one against Alarmforce, were voluntarily dismissed. The first was dismissed without prejudice, when Eyetalk withdrew their allegations. The second was dismissed with prejudice, when the parties settled their suits against each other.
Alarmforce agreed not to proceed against REVO and REVO agreed not to proceed against Alarmforce.
The myth of a royalty agreement was created by a PR from REVO, in which they announced the existence of a licensing agreement, but declined to provide any details because of an NDA.
Anyone who has followed REVO for any time knows that they hide their half truths behind NDAs. There is no evidence of a royalty agreement with Alarmforce.
will this situation render their patents null-and-void
No. The patents remain valid. They're just not of much commercial value.
The SEC action has no impact on the legality or marketability of the patents. The patents were not marketable before the suspension and the suspension doesn't change that uncomfortable reality.
Does anybody know if Ali and/ Carter received yearly salaries (cash) from the company?
Carter and Ali did not receive annual cash salaries from REVO. They paid themselves with shares and promissory notes. They sold those notes and shares to 'third party investors' to generate cash.
This absence of cash salaries reflects the fact that REVO has never generated a dollar from sales. It has only ever generated cash from its (three) private placements of restricted shares, and the sale of many loan notes.